Vetigenics Revenue
Biotechnology Research • 
Philadelphia, Pennsylvania, United States • 1-10 Employees
Vetigenics revenue & valuation
| Annual revenue | $855,550 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,800,000 |
| Total funding | $6,250,000 |
Key Contacts at Vetigenics
Yin Yin Chan
Director, Antibody Discovery
Lexi Pusey
Director, Operations And Quality Management
Company overview
| Headquarters | 2929 Arch St, Fl 4 Lab 436, Philadelphia, Pennsylvania 19104, US |
| Phone number | +12678752283 |
| Website | |
| NAICS | 541714 |
| Keywords | Animal Health, Immunotherapy, Veterinary Medicine, Antibodies, Cellular Therapy, Car-T |
| Founded | 2017 |
| Employees | 1-10 |
| Socials |
Vetigenics Email Formats
Vetigenics uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@vetigenics.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@vetigenics.com | 60% |
{first initial}{last name} | jdoe@vetigenics.com | 40% |
About Vetigenics
At Vetigenics, we harness the power of the animal's own immune system to bring the latest advancements in biotechnology to improve pet health. Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members. CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods. Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs. Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions. For more information contact: Adriann Sax, CEO asax@vetigenics.com
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Vetigenics has 2 employees across 2 departments.
Departments
Number of employees
Funding Data
Explore Vetigenics's funding history, including investment rounds, total capital raised, and key backers.
Vetigenics Tech Stack
Discover the technologies and tools that power Vetigenics's digital infrastructure, from frameworks to analytics platforms.
Caching
WordPress themes
Page builders
JavaScript libraries
JavaScript libraries
Programming languages
Security
Blogs
Analytics
SEO
Reverse proxies
WordPress plugins
United Kingdom
BrazilFrequently asked questions
4.8
40,000 users
